FDA rais­es ef­fi­ca­cy con­cerns with Y-mAb­s' po­ten­tial ther­a­py for pe­di­atric neu­rob­las­toma ahead of ODAC meet­ing

Ahead of a key meet­ing of the FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee to­mor­row, the FDA is rais­ing se­ri­ous con­cerns re­gard­ing the ef­fi­ca­cy of Y-mAbs Ther­a­peu­tics’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER